表柔比星联合紫杉醇新辅助化疗法治疗三阴性乳腺癌的效果分析

Effect analysis of epirubicin combined with paclitaxel neoadjuvant chemotherapy in the treatment of triple negative breast cancer

目的探讨表柔比星联合紫杉醇的新辅助化疗法治疗三阴性乳腺癌的临床疗效。方法选取我院治疗的110例三阴性乳腺癌患者为研究对象,按照不同的治疗方法分为对照组与治疗组,每组55例。对照组患者采取表柔比星治疗,治疗组采用表柔比星联合紫杉醇的新辅助化疗法治疗,对比两组患者的治疗效果、不良反应和Kamofsky评分。结果治疗组患者的总有效率显著高于对照组(P<0.05);两组不良反应发生率比较,无显著差异(P>0.05);治疗组患者的Kamofsky评分显著高于对照组(P<0.05)。结论表柔比星联合紫杉醇的新辅助化疗法治疗三阴性乳腺癌的疗效较好,值得进一步研究。

Objective To invesligale the clinical efficacy of epirubic combined with paclilaxel neoadjuvanl chemolherapy in lhe treatment of triple negative breast cancer. Methods A lolal of 110 palienls with triple negative breast cancer admitted in our hospital were selected as lhe research objects. All lhe palienls were divided into control group and treatment group according lo different treatment methods, with 55 cases in each group. The control group was treated with epirubicin, while lhe treatment group was treated with epirubicin combined with paclilaxel neoadjuvanl chemolherapy. The clinical effects, adverse reactions and Kamofsky scores of lhe lwo groups were compared. Results The lolal effective rale of treatment group was significantly higher than lhal of lhe control group （P〈0.05）. There was no significant difference on lhe incidence rale of adverse reactions between lhe lwo groups （P〉0.05）. The Kamofsky score of lhe treatment group was higher than lhal of lhe control group （P〈0.05）. Conclusion Epirubicin combined with paclilaxel neoadjuvanl chemolherapy in lhe treatment of triple negative breast cancer has significant clinical effect, which deserves further research.